Vitalis

Executive Summary

Vitalis Therapeutics is a clinical-stage biopharmaceutical company addressing the critical need for non-opioid pain management. Its lead candidate, VS-1, is an oral ketamine-based solution designed to manage acute post-operative pain, with an initial focus on patients undergoing total knee arthroplasty (TKA). The opioid crisis has underscored the urgent demand for effective, non-addictive analgesics, and VS-1 aims to provide a safer alternative that can reduce opioid reliance and improve recovery outcomes. By leveraging ketamine's well-established analgesic properties in a novel oral formulation, Vitalis targets a significant unmet need in the surgical pain market, which is dominated by opioids. Currently in clinical development, VS-1 has the potential to offer a differentiated profile with rapid onset, non-opioid mechanism, and favorable safety. The company is based in San Diego and benefits from a strong scientific foundation in neuroscience and psychiatry. While still early-stage, Vitalis's focused strategy on a high-volume surgical indication positions it for potential clinical and commercial success. If successful, VS-1 could become a cornerstone therapy in enhanced recovery after surgery (ERAS) protocols. The near-term focus will be on generating pivotal clinical data and advancing regulatory interactions to validate its approach and de-risk the program for future partnerships or financing.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 Topline Data for VS-1 in Total Knee Arthroplasty60% success
• Q2 2027FDA End-of-Phase 2 Meeting or IND Amendment75% success
• H2 2027Strategic Partnership or Licensing Agreement40% success